Johnson & Johnson has pulled ahead of rival AstraZeneca Plc in a race to dominate the blockbuster market for lung cancer ...

Astrazeneca (AZN) ended the recent trading session at $72.72, demonstrating a -0.45% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily loss of ...

AstraZeneca Plc‘s win over shareholders who challenged its $3 billion sale of biotech firm Viela Bio Inc. was affirmed Wednesday by the Delaware Supreme Court.

AstraZeneca already has cell therapies in its pipeline, and it is now expanding its scope further with a deal to acquire EsoBiotec, a company in early clinical development with therapies made by ...

AstraZeneca makes a deal to buy another biotech company, this one with a price tag that could reach $1 billion.

Multinational pharmaceutical company AstraZeneca is bullish about China's role as a global innovation powerhouse, underpinned ...

HONG KONG, LONDON] Ever since AstraZeneca shocked investors in October with news its China chief was under investigation, the ...

AstraZeneca is hopping on the pickleball craze for the latest iteration of its Stepping Back Out campaign for asthma treatment Fasenra.

The deal includes the Belgian biotech’s in-vivo cell-therapy platform, which modifies immune cells within the patient’s body, ...

The centre in Beijing will be the company's second R&D site in China - a centre in Shanghai opened in 2024 - to match two such centres each that AstraZeneca has in the U.S. and Europe ...

BEIJING] AstraZeneca will invest US$2.5 billion in a new research centre in Beijing, in a major show of commitment to China ...

AstraZeneca has a large presence in emerging markets and should benefit from these markets' fast growth prospects. The company's strong entrenchment in respiratory disease could cause challenges ...